Nastech Announces Multi-Compound Agreement with Novo Nordisk
News Mar 20, 2006
Nastech Pharmaceutical Company Inc. has announced that it has entered into a multi-compound, feasibility study agreement with Novo Nordisk A/S with respect to certain Novo Nordisk therapeutic compounds.
"Nastech is honored to be working with Novo Nordisk, a world-leader in therapies for metabolic disease," said Steven C. Quay, M.D., Ph.D., Chairman, President and CEO of Nastech.
"Novo Nordisk is known for its ethical standards and has participated in many innovative advances in medical practice."
Chemical Compound Class Possesses Potential for Treating Zika VirusNews
A new and promising class of chemical compounds has major potential for treating Zika virus and respiratory syncytial virus, or RSV, according to a new study.READ MORE
Lab Innovations 2018 – Registration Opens and Keynotes AnnouncedNews
Learn and earn CPD points at the UK’s only lab-dedicated showcase and scientific seminar series.READ MORE